Filing Flows › Apyx Medical (APYX) › Q3 2026 › vs Q3 2025
Apyx Medical (APYX) Q3 2026 vs Q3 2025 (year over year)
Apyx Medical's revenue rose $1.2M (+9%) from $12.9M in Q3 2025 to $14.0M in Q3 2026.
Apyx Medical, Q3 2026: revenue $14.0M (+9% year over year), operating margin -4.1%, net loss $1.8M, operating cash flow −$1.6M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $14.0M | $12.9M | $1.2M | +9% |
| Net loss | $1.8M | $2.0M | −$149K | -8% |
| Costs & expenses | $15.8M | $14.8M | $1.0M | +7% |
| Operating costs | $14.6M | $13.7M | $892K | +7% |
| Interest & other, net | $1.1M | $1.0M | $74K | +7% |
| Income tax | $116K | $78K | $38K | +49% |
| Cost of revenue | $5.0M | $4.6M | $449K | +10% |
| Research & development | $849K | $801K | $48K | +6% |
| SG&A | $4.0M | $3.8M | $164K | +4% |
| Other operating costs | $4.7M | $4.5M | $231K | +5% |
| Operating cash sources | $2.6M | $4.2M | −$1.7M | -39% |
| Depreciation & amortization | $187K | $164K | $23K | +14% |
| Share-based compensation | $753K | $530K | $223K | +42% |
| Cash used in operations | $1.6M | $3.5M | −$1.9M | -54% |
| Net loss absorbed | $1.8M | $2.0M | −$149K | -8% |
| Working capital & other | $768K | $2.3M | −$1.5M | -66% |
Questions
How much did Apyx Medical's revenue grow year over year in Q3 2026?
Apyx Medical's revenue rose $1.2M (+9%) from $12.9M in Q3 2025 to $14.0M in Q3 2026.